… gefitinib exposure and clinical outcome in gefitinib-treated patients with advanced non-small
cell lung cancer. … received 250-mg oral doses of gefitinib once daily. Blood samples were …

… lung disease (ILD) in Japanese patients with non-small-cell lung cancer who received
gefitinib. This study reports the association between gefitinib exposure and the occurrence of ILD. …

… in the pharmacokinetics of gefitinib at steady-state… lung cancer (NSCLC) who had been
treated with gefitinib. We focused on common polymorphisms within important gefitinib exposure …

… , poor metabolizers had no measurable O-desmethyl gefitinib, and the mean systemic
exposure to gefitinib was 2-fold higher in poor- versus extensive-metabolizer groups; higher than …

… It is currently unclear whether the T790M mutation occurred de novo during the gefitinib
exposure or if we simply picked out preexisting RPC-9 type cells from PC-9 culture. Consistent …

… , gefitinib adds to the list of recommended first-line treatments for lung cancer harboring EGFR
… , clinical efficacy, and safety of gefitinib in major clinical trials and post-marketing studies. …

… in patients showing minimal or stable response to gefitinib considering that A549 cells
have the intermediate sensitivity to gefitinib among lung cancer cell lines despite the K-ras …

… Gefitinib concentration in amniotic fluid, which represents chronic fetal exposure to the drug,
… both long half time elimination of gefitinib (ie 48 h) and long time exposure (ie 55 days). This …

… to gefitinib with IC 50 values of 40 nmol/L and 2 μmol/L, respectively. We examined the effects
of gefitinib on … sensitive (H1666) or resistant (A549 and H441) to gefitinib exposure in vitro. …

… of gefitinib resistance and select factors that determine sensitivity to gefitinib, we established
a human non-small cell lung … Exposure to gefitinib increased heterodimer formation in PC-9 …